SCHEMBL4289808

SCHEMBL4289808

CCCCNCCC(=O)Nc1ccc2c(c1)C(=O)c1cc(NC(=O)CCNCCCC)ccc1C2=O

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 2/20 0.61
TERT O14746 14/20 0.60
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
HPGD P15428 2/20 0.60
ALOX12 P18054 1/20 0.60
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
CYP1A2 P05177 1/20 0.58
POLB P06746 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
MAPT P10636 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298186 0.92 PTPRC (0.64) PTPRCTERTALDH1A1KDM4EHPGD
SCHEMBL4294896 0.88 TERT (0.74) PTPRCTERTALDH1A1MEN1NPC1
SCHEMBL4291487 0.87 TERT (0.74) PTPRCTERTALDH1A1MEN1NPC1
SCHEMBL4298269 0.84 PTPRC (0.83) PTPRCTERTALDH1A1KDM4EHPGD
SCHEMBL9312233 0.81 PTPRC (0.73) PTPRCTERTALDH1A1KDM4EHPGD
SCHEMBL8701507 0.80 TERT (0.78) PTPRCTERTALDH1A1KDM4EHPGD
SCHEMBL13663715 0.79 PTPRC (0.74) PTPRCTERTALDH1A1KDM4EHPGD
SCHEMBL4297885 0.79 TERT (0.78) PTPRCTERTALDH1A1MEN1NPC1
SCHEMBL17197048 0.79 HDAC1 (0.65) ALDH1A1MEN1CYP1A2POLBCYP2D6
SCHEMBL4299908 0.78 ALDH1A1 (0.90) PTPRCTERTALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 PTPRC 3899/4885TERT 1/4885ALDH1A1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.